DocWire News Editors

DocwireNews

A study presented at the 2020 ASH Annual Meeting found that loncastuximab, a humanized anti-CD19 antibody, had substantial single-agent anti-tumor activity in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).Adult patients (n=145) with relapsed/refractory DLBCL who failed two or more prior therapies were enrolled in the single-arm, open-label, phase II study. Patients received loncastuximab (mean number of cycles, 4.3; range, 1-15 cycles) and were followed for six or more months from the first dose.The overall response rate (ORR) was 48.3%, and the complete response (CR) rate was 24.1%. Median duration of response among the 70 patients who responded to loncastuximab was 10.3 months. For patients with a CR, median duration of response was 13.4 months. Most patients responded after two treatment cycles, with a median time to first response of 41 days.ORR was 44.8% in patients with transformed disease, 45.8% in patients aged 65 to 74 years, and 52.4% in patients aged &ge;75 years. For patients with double- or triple-hit DLBCL, ORR was 33.3%, all of which were CRs. Patients who were refractory to first-line therapy, most recent therapy, or any prior therapy had ORRs of 37.9%, 36.9%, and 36.0%, respectively. Patients who had previously undergone hematopoietic cell transplantation (HCT) had an ORR of 58.3%. The ORR was 46.2% in patients who received prior CD19-directed chimeric antigen receptor (CAR) T-cell therapy. Older patients had longer responses to treatment: &lt;65 years, 9.6 months; 65 to 74 years, 10.3 months; and &ge;75 years, 13.4 months.After treatment with loncastuximab, 15 patients received CD19-directed CAR-T therapy; the investigator-assessed ORR was 46.7%, including six CRs and one partial response. Nine patients who responded to loncastuximab went on to receive HCT as consolidation therapy.Almost all patients (n=143; 98.6%) had at least one treatment-related adverse event (AE), and 105 (72.4%) had grade &ge;3 AEs. The most common any-grade AEs were increased gamma-glutamyltransferase (GGT; 40.7%), neutropenia (39.3%), thrombocytopenia (33.1%), fatigue (27.6%), and anemia (26.2%). The most common grade &ge;3 AEs were neutropenia (25.5%), thrombocytopenia (17.9%), increased GGT (16.6%), and anemia (10.3%). Twenty-four patients (16.6%) discontinued treatment due to AEs, most commonly due to increased GGT (n=14; 9.7%). Patients aged &ge;65 years did not experience more AEs than younger patients.ReferenceCaimi PF, Ai WZ, Alderuccio JP, et al. Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Abstract 1183. Presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition, December 2-11, 2020.

Jordana Jampel

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

Pulmonology

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Latest News

Single-Agent Loncastuximab Induces Response in Patients with DLBCL

ASH Annual Meeting 2020

A study presented at the 2020 ASH Annual Meeting found that loncastuximab, a humanized anti-CD19 antibody, had substantial single-agent anti-tumor activity in patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe